Vertex Pharmaceuticals Inc (VRTX): Cost of Revenue
$1.65B
Year ended 2025-12-31
$1.76B
Trailing 12 months to 2026-06-30
+15.2%
3-year compound annual growth
+17.5%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.65B | +7.9% | 2026-02-13, From 2025-01-01 |
| 2024-12-31 | $1.53B | +21.3% | 2026-02-13, From 2024-01-01 |
| 2023-12-31 | $1.26B | +16.8% | 2026-02-13, From 2023-01-01 |
| 2022-12-31 | $1.08B | +19.5% | 2025-02-13, From 2022-01-01 |
| 2021-12-31 | $904.20M | +22.8% | 2024-02-15, From 2021-01-01 |
| 2020-12-31 | $736.30M | +34.4% | 2023-02-10, From 2020-01-01 |
| 2019-12-31 | $547.80M | +33.8% | 2022-02-09, From 2019-01-01 |
| 2018-12-31 | $409.54M | +48.9% | 2021-02-11, From 2018-01-01 |
| 2017-12-31 | $275.12M | +30.7% | 2020-02-13, From 2017-01-01 |
| 2016-12-31 | $210.46M | n/a | 2019-02-13, From 2016-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $1.65B | +7.9% |
| Viatris Inc (VTRS) | 2025-12-31 | $9.29B | +1.9% |
| Zoetis Inc. (ZTS) | 2025-12-31 | $2.67B | -1.9% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $8.32B | -1.9% |
| Organon & Co. (OGN) | 2025-12-31 | $2.90B | +8.0% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $2.12B | +5.9% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $2.76B | -2.5% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $677.17M | +120.9% |
| Abbott Laboratories (ABT) | 2025-12-31 | $19.32B | +3.3% |
Compare VRTX, VTRS, ZTS, TEVA side by side · Screen every company in Pharmaceutical Preparations ↗